Carboplatin equals cisplatin: But how do I prescribe it?

Journal of Clinical Oncology

Volumn 21, Issue 17, 2003, Pages 3183-3185

  Gore, Martin ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVARY CANCER; OVERALL SURVIVAL; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; FEMALE; NOTE; OVARY TUMOR;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0141465160     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.077     Document Type: Editorial

References (37)

1. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
2. Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92:699-708, 2000
3. McGuire WP, Hoskins WJ, Brady MF, et al: A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC): For the Gynecologic Oncology Group (GOG), Buffalo, NY 14263. Proc Am Soc Clin Oncol 12:255, 1993 (abstr 808)
4. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials-Advanced Ovarian Cancer Trialists Group. BMJ 303:884-893, 1991
5. Aabo K, Adams M, Adnitt P, et al: Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials-Advanced Ovarian Cancer Trialists' Group. Br J Cancer 78:1479-1487, 1998
6. Calvert AH, Boddy A, Bailey NP, et al: Carboplatin in combination with paclitaxel in advanced ovarian cancer: Dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 22:91-98, 1995 (suppl 12)
7. Siddiqui N, Bailey N, Memon M, et al: A phase I/pharmacokinetic study of escalating paclitaxel in combination with carboplatin dosed at a fixed area under the curve in epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:271, 1995 (abstr 752)
8. Neijt JP, Engelholm SA, Tuxen MK, et al: Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18:3084-3092, 2000
9. du Bois A, Nitz U, Schroder W, et al: Cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line chemotherapy in ovarian cancer: Interim analysis of an AGO Study Group trial. Proc Am Soc Clin Oncol 16:357a, 1997 (abstr 1272)
10. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003
11. Neijt JP, Hansen M, Hansen SW, et al: Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin: University Hospital Utrecht, 3584 CX Utrecht, The Netherlands and The Finsen Center, DK-2100 Copenhagen, Denmark. Proc Am Soc Clin Oncol 16:352a, 1997 (abstr 1259)
12. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
13. Jelliffe RW: Creatinine clearance: Bedside estimate. Ann Intern Med 79:604-605, 1973
14. Cockcroft D, Gault M: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
15. Levy AS, Perrone RD, Madias NE: Serum creatinine and renal function. Annu Rev Med 39:465-490, 1988
16. Shemesh O, Golbetz H, Kriss JP, et al: Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28:830-838, 1985
17. Ando Y, Minami H, Saka H, et al: Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing. Br J Cancer 76:1067-1071, 1997
18. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, et al: Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 37:266-270, 1996
19. Chatelut E, Canal P, Brunner V, et al: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573-580, 1995
20. Calvert AH: A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin Oncol 24:85-90, 1997 (1 suppl 2)
21. Wright JG, Boddy AV, Highley M, et al: Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84:452-459, 2001
22. Martin L, Chatelut E, Boneu A, et al: Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer 85:631-636, 1998
23. Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation-Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470, 1999
24. Dooley MJ, Poole SG, Rischin D, et al: Carboplatin dosing: Gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer 38:44-51, 2002
25. Joly F, Heron JF, Kerbrat P, et al: High-dose platinum versus standard dose in advanced ovarian carcinoma: A randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Gynecol Oncol 78:361-368, 2000
26. Dittrich Ch, Sevelda P, Salzer H, et al: Lack of impact of platinum dose intensity on the outcome of ovarian Cancer patients: 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Eur J Cancer 39:1129-1140, 2003
27. Conte PF, Bruzzone M, Carnino F, et al: High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: A randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 14:351-356, 1996
28. McGuire WP, Hoskins WJ, Brady MF, et al: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 13:1589-1599, 1995
29. Kaye SB, Lewis CR, Paul J, et al: Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340:329-333, 1992
30. Kaye SB, Paul J, Cassidy J, et al: Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 14:2113-2119, 1996
31. van der Burg ME, de Wit R, van Putten WL, et al: Weekly cisplatin and daily oral etoposide is highly effective in platinum pre-treated ovarian cancer. Br J Cancer 86:2-4, 2002
32. Gore M, Mainwaring P, A'Hern R, et al: Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol 16:2426-2434, 1998
33. Jakobsen A, Bertelsen K, Andersen JE, et al: Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group study. J Clin Oncol 15:193-198, 1997
34. Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520-528, 1992
35. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950-1955, 1996
36. Markman M, Bundy BN, Alberts DS, et al: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007, 2001
37. Armstrong DK, Bundy BN, Baergen R, et al: Randomised phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 172). Proc Am Soc Clin Oncol 21:201a, 2002 (abstr 803)